stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Return on equity
Summit Therapeutics PLC's return on equity over the twelve months to 30 June 2026 was −192.5%, up 13.6 percentage points from fiscal 2025 (−206.1%). Over the past ten years it has ranged from −630.7% (fiscal 2018) to 628.3% (fiscal 2017); the current reading is higher than 33% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −206.1% | (111.20) |
| FY2024 | −94.9% | 506.95 |
| FY2023 | −601.9% | (526.80) |
| FY2022 | −75.1% | 33.84 |
| FY2021 | −108.9% | (42.32) |
| FY2020 | −66.6% | (23.52) |
| FY2019 | −43.1% | (81.52) |
| FY2019 | 38.5% | 669.13 |
| FY2018 | −630.7% | (411.18) |
| FY2018 | −219.5% | (847.77) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 216.4% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| TECH Bio-Techne Corp compare | 9.03% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| KYMR Kymera Therapeutics, Inc. compare | −27.3% |
| PCVX Vaxcyte, Inc. compare | −36.5% |
| SMMT Summit Therapeutics PLC | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement